Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16302718 | 0.81 | ADORA3 (0.57) | ADORA3ADORA2AMEN1KMT2AL3MBTL1 | |
| SCHEMBL21338154 | 0.81 | ADORA3 (0.57) | ADORA3ADORA2AMEN1KMT2AGAA | |
| SCHEMBL13633450 | 0.80 | MEN1 (0.48) | ADORA3ADORA2AMEN1KMT2AGAA | |
| SCHEMBL4249530 | 0.80 | ADORA3 (0.56) | ADORA3ADORA2AMEN1KMT2AL3MBTL1 | |
| SCHEMBL15009258 | 0.79 | MEN1 (0.51) | ADORA3ADORA2AMEN1KMT2AGAA | |
| SCHEMBL16308047 | 0.79 | MEN1 (0.51) | ADORA3ADORA2AMEN1KMT2AGAA | |
| SCHEMBL1489997 | 0.79 | ATF1 (0.48) | ADORA3ADORA2ASMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL115774 | 0.77 | NPC1 (0.48) | ADORA3ADORA2AMEN1KMT2AGAA | |
| SCHEMBL9672815 | 0.77 | KMT2A (0.45) | MEN1KMT2AGAASMN1; SMN2POLB | |
| SCHEMBL25699611 | 0.77 | PIK3C3 (0.48) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709503-B2 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1664025-B1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| EP-1664025-A1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026149-A1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | PEF1, PEPD, PELP1 | ADORA3 4719/4885ADORA2A 4760/4885MEN1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.